Accordingly, the use of FOXM1i might also serve to sensitize SCLC cells or tumors to immune-based therapies, as in our bulk RNA-seq studies following FOXM1i treatment, we have also seen an upregulation of inflammatory chemokines (prominent ones are IL24, CXCL8, and CCL3 and its analogues) gene expression (Fig. S6A), suggesting that FOXM1i may have an impact on T cell activation and T cell-mediated killing of SCLC cells. Here, CCL3 is linked to small cell lung carcinoma.